Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (MBRX): 4 pipeline candidates · 1 upcoming catalyst · ~5 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
5.2 months
D/E 0.54 · 0% dilution
Lead: Phase 2/Phase 3
4 candidates
1 upcoming, next in ~1505d
N/A
A transparent, data-derived signal for Moleculin Biotech, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$14.5M
Cash
$10.3M
Quarterly Burn
$6.1M
Runway
5.2 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| annamycin | Phase 2/Phase 3 |
| liposomal annamycin | Phase 2/Phase 3 |
| liposomal annamycin injection in combination with cytarabine | Phase 2/Phase 3 |
| wp1066 | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$326K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 75,021 | $172K |
| geode capital management, llc | 32,329 | $74K |
| vanguard capital management llc | 27,738 | $64K |
| vanguard fiduciary trust co | 6,072 | $14K |
| blackrock, inc. | 491 | $1K |
| pinnacle wealth planning services, inc. | 281 | $643 |
| nfsg corp | 114 | $261 |
| sbi securities co., ltd. | 43 | $98 |
| morgan stanley | 36 | $83 |
| vanguard global advisers, llc | 24 | $55 |
Showing top 10 of 16 institutional holders of Moleculin Biotech, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Moleculin Biotech, Inc.'s pipeline?
Moleculin Biotech, Inc. (MBRX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Moleculin Biotech, Inc.'s lead drug candidate?
Moleculin Biotech, Inc.'s most advanced tracked candidate is annamycin (Phase 2/Phase 3) for Leukemia, Myeloid, Acute.
What is Moleculin Biotech, Inc.'s next catalyst?
Moleculin Biotech, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Stu" — expected August 1, 2030.
What is Moleculin Biotech, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Moleculin Biotech, Inc. has approximately 5.2 months of cash runway.
What is Moleculin Biotech, Inc.'s market capitalization?
Moleculin Biotech, Inc.'s market capitalization is approximately $14.5M.
Get the full picture on Moleculin Biotech, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.